Thanks, dewo—I think we’re on the same wavelength vis-à-vis ANA598. I would just add that the parallels to NM283 are considerable and if ANA598 belonged to a Big Pharma, I don’t think the program would be going forward. In other words, I consider the ANA598 program a case of Zebra’s Law.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”